Skip to main content
. 2024 Mar 15;14:1347297. doi: 10.3389/fonc.2024.1347297

Table 2.

Demographic and clinicopathological characteristics of patients in the training set.

Characteristic Non-PICC-RVTE (n = 194) PICC-RVTE (n = 21) P
Demographic characteristics
Age (years) 1.938 0.126
≤60 131 (67.5) 11 (52.4)
>60 63 (32.5) 10 (47.6)
Gender 0.104 0.469
Male 113 (58.2) 13 (61.9)
Female 81 (41.8) 8 (38.1)
Diagnosis 2.945 0.067
Non-Hodgkin’s
 lymphoma (NHL)
155 (79.9) 20 (95.2)
Hodgkin’s
 lymphoma (HL)
39 (20.1) 1 (4.8)
Activity amount 10.161 0.009
Hardly 10 (5.2) 5 (23.8)
Frequently 184 (94.8) 16 (76.2)
Surgical history (within the last 6 months) 0.107 0.458
No 118 (60.8) 12 (57.1)
Yes 76 (39.2) 9 (42.9)
PICC history of blood transfusion (within the last 6 months) 9.337 0.009
No 179 (92.3) 15 (71.4)
Yes 15 (7.7) 6 (28.6)
KPS score 5.098 0.023
≥90points 123 (63.4) 8 (38.1)
≤80 points 71 (36.6) 13 (61.9)
BMI (kg/m2) 0.287 0.425
≤25 157 (80.9) 18 (85.7)
>25 37 (19.1) 40 (14.3)
smoking history 2.064 0.120
No 140 (72.2) 12 (57.1)
Yes 54 (27.8) 9 (42.9)
drinking history 4.142 0.052
No 170 (87.6) 15 (71.4)
Yes 24 (12.4) 6 (28.6)
Co-infection 8.053 0.009
No 161 (83.0) 12 (57.1)
Yes 33 (17.0) 9 (42.9)
Hormone use 0.408 0.381
No 39 (20.1) 3 (14.3)
Yes 155 (79.9) 18 (85.7)
Hypertension 0.100 0.547
No 171 (88.1) 19 (90.5)
Yes 23 (11.9) 2 (9.5)
Diabetes mellitus 0.070 0.567
No 187 (96.4) 20 (95.2)
Yes 7 (3.6) 1 (4.8)
Hyperlipidemia 3.334 0.069
No 161 (83.0) 14 (66.7)
Yes 33 (17.0) 7 (33.3)
Thrombosis history (within the last 12 months) 18.604 0.001
No 186 (95.9) 15 (71.4)
Yes 8 (4.1) 6 (28.6)
Laboratory data
RBC (1012/l) 1.938 0.124
 ≤4.0 63 (32.5) 10 (47.6)
 >4.0 131 (67.5) 11 (52.4)
WBC* (109/l) 0.770 0.680
<4 47 (24.2) 6 (28.6)
4-10 120 (61.9) 11 (52.4)
>10 27 (13.9) 4 (19.0)
PLT (109/l) 0.183 0.913
<100 22 (11.3) 3 (14.3)
100-300 131 (67.5) 14 (66.7)
>300 41 (21.1) 4 (19.0)
HGB (g/l) 0.282 0.381
≤110 140 (72.2) 14 (66.7)
>110 54 (27.8) 7 (33.3)
HCT 1.804 0.133
≤40 109 (56.2) 15 (71.4)
>40 85 (43.8) 6 (28.6)
PT (s) 0.081 0.481
≤12.1 41 (21.1) 5 (23.8)
>12.1 153 (78.9) 16 (76.2)
INR 0.068 0.543
≤1.06 162 (83.5) 18 (85.7)
>1.06 32 (16.5) 3 (14.3)
APTT (s) 2.872 0.082
≤39.6 152 (78.4) 13 (61.9)
>39.6 42 (21.6) 8 (38.1)
TT 0.442 0.336
≤15 43 (22.2) 6 (28.6)
>15 151 (77.8) 15 (71.4)
FIB 7.004 0.008
≤4 114 (58.8) 6 (28.6)
>4 80 (41.2) 15 (71.4)
ATIII 6.339 0.013
≤97.5 66 (34.0) 13 (61.9)
>97.5 128 (66.0) 8 (38.1)
FDP 2.084 0.121
<5 148 (76.3) 13 (61.9)
≥5 46 (23.7) 8 (38.1)
D-Dimer (mg/L)
≤0.55 102 (52.9) 4 (19.0) 8.523 0.003
>0.55 92 (47.4) 17 (81.0)
Albumin (g/L) 4.594 0.040
≤35.5 29 (14.9) 7 (33.3)
>35.5 165 (85.1) 14 (66.7)
Albumin/Globulin 1.357 0.178
≤1.62 59 (30.4) 9 (42.9)
>1.62 135 (69.6) 12 (57.1)
Total bilirubin (μmol/L) 1.981 0.119
≤9.05 96 (49.5) 7 (33.3)
>9.05 98 (50.5) 14 (66.7)
Total cholesterol (mmol/L) 3.895 0.048
<5.36 149 (76.8) 12 (57.1)
≥5.36 45 (23.2) 9 (42.9)
Fasting Blood Glucose (mmol/l) 1.171 0.244
<6.11 169 (87.1) 20 (95.2)
≥6.11 25 (12.9) 1 (4.8)
Indicators related to PICC placement
Catheter type n (%) 0.030 0.529
4Fr 160 (82.5) 17 (81.0)
5Fr 34 (17.5) 4 (19.0)
History of central venous catheterization 0.771 0.262
yes 110 (56.7) 14 (66.7)
no 84 (43.3) 7 (33.3)
Catheter side n (%) 0.503 0.333
Left 168 (86.6) 17 (81.0)
Right 26 (13.4) 4 (19.0)
Punctured vein n (%) 4.272 0.118
Precious Veins 182 (93.8) 18 (85.7)
Brachial vein 11 (5.7) 2 (9.5)
Cephalic vein 1 (0.5) 1 (4.8)
Position of catheter tip n (%) 30.503 <0.001
Upper half of superior vena cava 6 (3.1) 7 (33.3)
Lower half of superior vena cava 188 (96.9) 14 (66.7)

KPS score, Karnofsky Performance Status score; BMI, Body Mass Index; RBC, Red Blood Cell; WBC, White Blood Cell; PLT, Platelet; HGB, Hemoglobin; HCT, Hematocrit; PT, Prothrombin Time; INR, International Normalized Ratio; APTT, Activated Partial; Thromboplastin Time; TT, Thrombin Time; FIB, Fibrinogen; ATIII, Antithrombin III; FDP, Fibrinogen Degradation Products.